• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning Expertise

    4/1/26 9:00:00 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care
    Get the next $NEPH alert in real time by email

    SOUTH ORANGE, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced an expansion of its customer-facing, water-safety support capabilities following the ASSE 12080 Legionella Water Safety and Management Specialist Certification earned by Brianne McGuire, Director of Business Development. The certification strengthens Nephros' ability to provide consultative support to healthcare facilities and other complex buildings seeking to reduce waterborne pathogen risk and adds specific proficiency in the development of effective Water Management Programs (WMPs).

    This new capability marks a meaningful extension of Nephros' field support for customers seeking more robust water safety programs. In addition to point-of-use filtration solutions, product installations and replacements, as well as public education, Nephros can now provide a direct Water Management Program development service. Water Management Programs offer a structured framework for identifying water-quality risks, establishing control measures, assigning responsibility, and defining ongoing monitoring and response. The company believes this offering will create additional value for customers while opening a new avenue for revenue generation through chargeable consulting service.

    Nephros considers this support expansion to be differentiated by the depth of practical knowledge informing it. Besides the new ASSE 12080 certification, Ms. McGuire brings broad experience in technical concerns, waterborne risk, current guidance and standards, and industry best practices born out of direct engagement with healthcare facilities and other regulated environments. Her leadership of the Nephros Water Institute and other company public education initiatives has further expanded the company's perspective on how complex water safety risks are understood and addressed in practice. As a result, Nephros believes it is well-positioned to apply a diverse scope of understanding to the design of WMPs informed by extensive practical expertise in risk, implementation and real-world operational challenges.

    "Water management planning is a natural and important extension of our current customer care and engagement," said Robert Banks, President and Chief Executive Officer of Nephros. "We believe this new capability will allow us to engage more deeply in a facility's decision-making process, while offering a service guided by both certified proficiency and comprehensive knowledge of the unique challenges faced by healthcare entities. As a result, we believe this strengthens our overall value proposition while creating another meaningful method of growing our business and advancing the pursuit of advanced water safety and quality."

    About Nephros

    Nephros is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros products serve the needs of customers within healthcare and commercial markets, offering both proactive and emergency solutions for water management.

    For more information about Nephros, please visit nephros.com.

    Forward-Looking Statements

    This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the expected benefits that Nephros will realize from its water management program consulting service offering, including the potential for realizing additional revenue from such offering, the expected competitive advantages and anticipated impact of new water management program services and customer education offerings, and other statements that are not historical facts, including statements that may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including Nephros' ability to further develop its sales organization and realize increased revenues, the extent to which financial results based on emergency response sales can be outside Nephros' control, U.S. tariff and trade policy, inflationary factors and other economic and competitive conditions, the availability of capital when needed, dependence on third-party manufacturers and researchers, and regulatory reforms. These and other risks and uncertainties are detailed in Nephros' reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of this release, and Nephros does not undertake any responsibility to update any forward-looking statements that it makes, except as may be required by law.

    Investor Relations Contacts:

    Kirin Smith, President

    PCG Advisory, Inc.

    (646) 823-8656

    [email protected]

    Robert Banks, CEO

    Nephros, Inc.

    (201) 343-5202 x110

    [email protected]



    Primary Logo

    Get the next $NEPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NEPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley FBR initiated coverage on Nephros with a new price target

    B. Riley FBR initiated coverage of Nephros with a rating of Buy and set a new price target of $12.50

    1/26/21 6:12:57 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Banks Robert R. Jr.

    4 - NEPHROS INC (0001196298) (Issuer)

    3/25/26 4:54:04 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Krandel Judy

    4 - NEPHROS INC (0001196298) (Issuer)

    3/25/26 4:53:39 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Nephros Inc.

    4 - NEPHROS INC (0001196298) (Issuer)

    3/18/26 5:23:08 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $NEPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $NEPH
    SEC Filings

    View All

    Nephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning Expertise

    SOUTH ORANGE, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced an expansion of its customer-facing, water-safety support capabilities following the ASSE 12080 Legionella Water Safety and Management Specialist Certification earned by Brianne McGuire, Director of Business Development. The certification strengthens Nephros' ability to provide consultative support to healthcare facilities and other complex buildings seeking to reduce waterborne pathogen risk and adds specific proficiency in the development of effective Water Management Programs (WMPs).

    4/1/26 9:00:00 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    ­­Nephros Announces Fourth Quarter and Record Fiscal Year 2025 Financial Results

    Full-Year Net Revenue Increased 33% Y-O-Y to $18.8 Million and Fourth-Quarter Net Revenue up 22% Y-O-Y to $4.7 Million Reports Second Consecutive Year of Positive Net Income SOUTH ORANGE, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025. Financial HighlightsFourth Quarter Ended December 31, 2025. Net revenue was $4.7 million, compared to $3.9 million in the fourth quarter of 2024, up 22%Net income was $62,000, compared to $349,000 during the same period in 2024Adjust

    3/12/26 4:10:00 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros Schedules Fourth Quarter 2025 Financial Results Conference Call

    SOUTH ORANGE, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth-quarter financial results on Thursday, March 12, 2026 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a replay of

    3/5/26 7:04:28 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Amron Arthur H bought $11,176 worth of shares (5,000 units at $2.24), increasing direct ownership by 5% to 103,463 units (SEC Form 4)

    4 - NEPHROS INC (0001196298) (Issuer)

    5/30/24 4:35:22 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Banks Robert R. Jr. bought $112,050 worth of shares (50,000 units at $2.24), increasing direct ownership by 250% to 70,000 units (SEC Form 4)

    4 - NEPHROS INC (0001196298) (Issuer)

    5/16/24 4:49:44 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Amron Arthur H bought $17,130 worth of shares (7,000 units at $2.45) and acquired 91,463 shares (SEC Form 4)

    4 - NEPHROS INC (0001196298) (Issuer)

    3/14/24 4:28:20 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NEPHROS INC (0001196298) (Filer)

    3/27/26 4:00:44 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Nephros Inc.

    10-K - NEPHROS INC (0001196298) (Filer)

    3/12/26 4:01:16 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

    8-K - NEPHROS INC (0001196298) (Filer)

    11/26/25 4:15:32 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    Leadership Updates

    Live Leadership Updates

    View All

    Nephros Hires Judy Krandel as Chief Financial Officer

    SOUTH ORANGE, NJ, Nov. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In this role, Ms. Krandel will be responsible for directing the company's finances and working closely with the Chief Executive Officer (CEO) and Board of Directors to develop and execute Nephros's long-term strategy. Ms. Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years of experience in asset management, inv

    11/1/23 7:30:00 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros Appoints Joe Harris to Its Board of Directors

    SOUTH ORANGE, NJ, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Joe Harris to its Board of Directors. "We are excited that Joe is joining our board," said Andy Astor, President and Chief Executive Officer of Nephros. "He brings years of financial, sales, and marketing acumen to the board, with experience in both large and small healthcare ventures." "I am thrilled to join the Nephros board," said Joe Harris. "I believe Nephros is at an exciting point as they continue to focus on sales moment

    9/8/22 4:00:00 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    RION Appoints Alisa Lask as Chief Commercial Officer

    - Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov

    1/14/22 9:00:00 AM ET
    $CLGN
    $NEPH
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    $NEPH
    Financials

    Live finance-specific insights

    View All

    ­­Nephros Announces Fourth Quarter and Record Fiscal Year 2025 Financial Results

    Full-Year Net Revenue Increased 33% Y-O-Y to $18.8 Million and Fourth-Quarter Net Revenue up 22% Y-O-Y to $4.7 Million Reports Second Consecutive Year of Positive Net Income SOUTH ORANGE, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025. Financial HighlightsFourth Quarter Ended December 31, 2025. Net revenue was $4.7 million, compared to $3.9 million in the fourth quarter of 2024, up 22%Net income was $62,000, compared to $349,000 during the same period in 2024Adjust

    3/12/26 4:10:00 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros Schedules Fourth Quarter 2025 Financial Results Conference Call

    SOUTH ORANGE, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth-quarter financial results on Thursday, March 12, 2026 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a replay of

    3/5/26 7:04:28 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    ¬Nephros Schedules Third Quarter 2025 Financial Results Conference Call

    SOUTH ORANGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 6, 2025 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a replay of

    10/30/25 4:00:00 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nephros Inc.

    SC 13G - NEPHROS INC (0001196298) (Subject)

    2/3/23 3:15:24 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Nephros Inc.

    SC 13G - NEPHROS INC (0001196298) (Subject)

    2/3/23 3:13:44 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Nephros Inc.

    SC 13G - NEPHROS INC (0001196298) (Subject)

    2/3/23 3:11:33 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care